Distinct Neurostructural, Cognitive, and Neuropsychiatric Associations of Plasma p-tau217, and Aβ42/40 in Parkinson’s Disease and Aging Cohorts
Objective: To investigate associations between plasma biomarkers of Alzheimer’s disease (AD) pathology [phosphorylated-tau-217 (p-tau217), amyloid-beta-42/40 (Aβ42/40)], neurodegeneration [neurofilament light chain (NfL)], and neuroinflammation [glial fibrillary…Clinical Predictors of Cognitive Decline in Parkinson’s Disease: A Longitudinal Cohort Study
Objective: To identify clinical predictors associated with progression of cognitive impairment in patients with Parkinson’s disease. Background: Cognitive impairment is a common non-motor manifestation of…Clinical Evaluation of TT-P34: Exploring Safety and CSF Exposure in Parkinson’s Disease Patients
Objective: Evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TT-P34 in cerebrospinal fluid (CSF) following multiple subcutaneous (SC) doses in Parkinson’s disease patients…Dysregulation of the Intestinal Macrophage CXCL8/CXCR2 Axis and Its Role in α-Synuclein Clearance
Objective: To investigate the role of the CXCL8/CXCL2–CXCR2 axis in intestinal macrophage-mediated clearance of α-syn in PD. Background: PD is characterized by the misfolding, aggregation,…Impact of foslevodopa/foscarbidopa infusion on autonomic symptoms in advanced Parkinson’s Disease
Objective: To investigate the impact of continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) on autonomic symptoms in patients with advanced Parkinson’s disease (aPD) Background: CSFLI is a…Continuous Subcutaneous Foslevodopa/Foscarbidopa After Deep Brain Stimulation or Levodopa–Carbidopa Intestinal Gel: A Case Series in Advanced Parkinson’s Disease
Objective: To describe indications and short-term outcomes of FLC/FCD in PD patients previously treated with DBS and/or LCIG. Background: Advanced Parkinson's disease patients treated with…Associations Between Saccadic and Motoric Symptoms in Parkinson’s Disease
Objective: To explore associations between saccadic measures and i) global motor, ii) non-tremor motor, and iii) tremor severity in Parkinson’s disease (PD). Background: Impaired voluntary…Volatile Organic Compound Signatures Differentiate Parkinson Disease from Parkinson Disease Mimic Syndromes and Controls
Objective: We aimed to isolate volatile organic compounds (VOCs) in cerumen and sebum samples from participants with Parkinson disease (PD), PD-mimic syndromes, Idiopathic REM Sleep…Reduced Cardiac MIBG Uptake as a Biomarker for Nucleus Basalis of Meynert Degeneration and Cognitive Impairment in Parkinson’s Disease
Objective: Cognitive impairment is a critical issue in the advanced stages of Parkinson’s disease (PD) [1]. Similar to other neurodegenerative diseases, degeneration of the nucleus…Objective Characteristics and Brain Network Alterations in Early-Stage Parkinson’s Disease with Gastric Motility Disorder
Objective: To characterize objective gastric motility disorder (GMD) in early-stage Parkinson’s disease (PD) and explore the underlying central neural network and structural alterations using multimodal…
- « Previous Page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- …
- 553
- Next Page »